Browse By: Country ι Category ι Latest Reports ι Tag
Home  »  Global Markets Direct

Global Markets Direct Market Research Reports

Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials.

At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.

Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016’, provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics. The report provides comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2016’, provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted pipeline therapeutics. The report provides comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacologi
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, i
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted pipeline therapeutics. The report provides comprehensive information on the TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 3 (CD283 or TLR3) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development and features dormant and disco
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and disco
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2016’, provides in depth analysis on Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted pipeline therapeutics. The report provides comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete res
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
RAC Alpha Serine-Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $3500
Aeterna Zentaris Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Aeterna Zentaris Inc. - Product Pipeline Review - 2016’, provides an overview of the Aeterna Zentaris Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Aeterna Zentaris Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Caladrius Biosciences, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Caladrius Biosciences, Inc. - Product Pipeline Review - 2016’, provides an overview of the Caladrius Biosciences, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Caladrius Biosciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is bu
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
ContraFect Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘ContraFect Corporation - Product Pipeline Review - 2016’, provides an overview of the ContraFect Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by ContraFect Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Galapagos NV - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Galapagos NV - Product Pipeline Review - 2016’, provides an overview of the Galapagos NV’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Galapagos NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from G
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Green Cross Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Green Cross Corporation - Product Pipeline Review - 2016’, provides an overview of the Green Cross Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Green Cross Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using da
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Immunovaccine, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Immunovaccine, Inc. - Product Pipeline Review - 2016’, provides an overview of the Immunovaccine, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Immunovaccine, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and infor
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Inovio Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Inovio Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ligand Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Momenta Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016’, provides an overview of the RXi Pharmaceuticals Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by RXi Pharmaceuticals Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sarepta Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sarepta Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $1500
Post-Operative Pain - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Post-Operative Pain - Pipeline Review, H2 2016’, provides an overview of the Post-Operative Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Sepsis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Sepsis - Pipeline Review, H2 2016’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy a
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Intermittent Claudication - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Intermittent Claudication - Pipeline Review, H2 2016’, provides an overview of the Intermittent Claudication pipeline landscape. The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Cerebral Palsy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Cerebral Palsy - Pipeline Review, H2 2016’, provides an overview of the Cerebral Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Fatigue - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Fatigue - Pipeline Review, H2 2016’, provides an overview of the Fatigue pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 thera
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Hyperalgesia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Hyperalgesia - Pipeline Review, H2 2016’, provides an overview of the Hyperalgesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Hidradenitis Suppurativa - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Hidradenitis Suppurativa - Pipeline Review, H2 2016’, provides an overview of the Hidradenitis Suppurativa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. Global Markets Direct’s report fea
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Hepatic Encephalopathy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Hepatic Encephalopathy - Pipeline Review, H2 2016’, provides an overview of the Hepatic Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. Global Markets Direct’s report features in
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Nocturia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Nocturia - Pipeline Review, H2 2016’, provides an overview of the Nocturia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nocturia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Ragweed Allergy - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Ragweed Allergy - Pipeline Review, H2 2016’, provides an overview of the Ragweed Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from acr
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Bacterial Vaginosis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Bacterial Vaginosis - Pipeline Review, H2 2016’, provides an overview of the Bacterial Vaginosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Cholera - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Cholera - Pipeline Review, H2 2016’, provides an overview of the Cholera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 thera
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Phenylketonuria (PKU) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Phenylketonuria (PKU) - Pipeline Review, H2 2016’, provides an overview of the Phenylketonuria (PKU) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Phenylketonuria (PKU) and features dormant and discontinued projects. Global Markets Direct’s report features invest
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Acute Heart Failure - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Acute Heart Failure - Pipeline Review, H2 2016’, provides an overview of the Acute Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016’, provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. Glob
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016’, provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease and features dormant and discontinued projects. Global Markets Direct’
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Nerve Injury - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Nerve Injury - Pipeline Review, H2 2016’, provides an overview of the Nerve Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Primary Biliary Cirrhosis - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Primary Biliary Cirrhosis - Pipeline Review, H2 2016’, provides an overview of the Primary Biliary Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Down Syndrome - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Down Syndrome - Pipeline Review, H2 2016’, provides an overview of the Down Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Urinary Incontinence - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Urinary Incontinence - Pipeline Review, H2 2016’, provides an overview of the Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Plague - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Plague - Pipeline Review, H2 2016’, provides an overview of the Plague pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy a
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Community Acquired Pneumonia - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H2 2016’, provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. Global Markets Direc
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Smallpox - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Smallpox - Pipeline Review, H2 2016’, provides an overview of the Smallpox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Secondary Hyperparathyroidism - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Secondary Hyperparathyroidism - Pipeline Review, H2 2016’, provides an overview of the Secondary Hyperparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. Global Markets D
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Helicobacter pylori Infections - Pipeline Review, H2 2016
Summary Global Markets Direct’s, ‘Helicobacter pylori Infections - Pipeline Review, H2 2016’, provides an overview of the Helicobacter pylori Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects. Global Marke
Published Date: Jul 2016
Published By: Global Markets Direct

Price: $2000
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer-Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) - Pipeline Review, H1 2016’, provides in depth analysis on Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) targeted pipeline therapeutics. The report provides comprehensive information on the Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological actio
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Steroid 17-Alpha-Hydroxylase-17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipelin
Summary Global Markets Direct’s, ‘Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipeline Review, H1 2016’, provides in depth analysis on Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) targeted pipeline therapeutics. The report provides comprehensive information on the Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or C
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016’, provides in depth analysis on 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted pipeline therapeutics. The report provides comprehensive information on the 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H1 2016’, provides in depth analysis on Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted pipeline therapeutics. The report provides comprehensive information on the Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and mol
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncy
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016’, provides in depth analysis on Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information on the Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overv
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Hemagglutinin 5 (H5) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hemagglutinin 5 (H5) - Pipeline Review, H1 2016’, provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics. The report provides comprehensive information on the Hemagglutinin 5 (H5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features inv
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016’, provides in depth analysis on Hepatitis B Virus Core Antigen (HBcAg) targeted pipeline therapeutics. The report provides comprehensive information on the Hepatitis B Virus Core Antigen (HBcAg), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics development and features dormant a
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016’, provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics. The report provides comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics develo
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) - Pipeline Review, H1 2016’, provides in depth analysis on Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2) targeted pipeline therapeutics. The report provides comprehensive information on the Survival Motor Neuron Protein (Component Of Gems 1 or Gemin-1 or SMN1 or SMN2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016’, provides in depth analysis on Trans-Activator Of Transcription (Tat) targeted pipeline therapeutics. The report provides comprehensive information on the Trans-Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Trans-Activator Of Transcription (Tat) targeted therapeutics development and features dormant a
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provi
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Pipeline Review, H1 2016’, provides in depth analysis on Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted pipeline therapeutics. The report provides comprehensive information on the Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its comple
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cyclin-Dependent Kinase 5 (Serine-Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016’, provides in depth analysis on Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information on the Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
MAP Kinase-Interacting Serine-Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of act
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
MAP Kinase-Interacting Serine-Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of act
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
BDNF-NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, m
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administra
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Arbutus Biopharma Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Arbutus Biopharma Corporation - Product Pipeline Review - 2016’, provides an overview of the Arbutus Biopharma Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Arbutus Biopharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Cocrystal Pharma, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Cocrystal Pharma, Inc. - Product Pipeline Review - 2016’, provides an overview of the Cocrystal Pharma, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
EpiVax, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘EpiVax, Inc. - Product Pipeline Review - 2016’, provides an overview of the EpiVax, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by EpiVax, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from G
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the HanAll Biopharma Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by HanAll Biopharma Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Kancera AB - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Kancera AB - Product Pipeline Review - 2016’, provides an overview of the Kancera AB’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kancera AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sorrento Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sorrento Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is bu
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016’, provides an overview of the Takeda Pharmaceutical Company Limited’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Breast Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Breast Cancer - Pipeline Review, H1 2016’, provides an overview of the Breast Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Melanoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Melanoma - Pipeline Review, H1 2016’, provides an overview of the Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 t
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
HIV - AIDS - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘HIV / AIDS - Pipeline Review, H1 2016’, provides an overview of the HIV / AIDS pipeline landscape. The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HIV / AIDS and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering o
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Colorectal Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Colorectal Cancer - Pipeline Review, H1 2016’, provides an overview of the Colorectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016’, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acu
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Review, H1 2016’, provides in depth analysis on Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted pipeline therapeutics. The report provides comprehensive information on the Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also cover
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin X o
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) - Pipeline Review, H1 2016’, provides in depth analysis on 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24) targeted pipeline therapeutics. The report provides comprehensive information on the 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or MMP2 or EC 3.4.24.24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 15 (IL15) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Interleukin 15 (IL15) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 15 (IL15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016’, provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted pipeline therapeutics. The report provides comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report p
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016’, provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics. The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects. G
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016’, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Rece
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) - Pipeline Review, H1 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted pipeline therapeutics. The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016’, provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics. The report provides comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development and fe
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its comple
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘ Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016’, provides in depth analysis on  Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted pipeline therapeutics. The report provides comprehensive information on the  Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in  Interleukin 7 Receptor Subunit Alpha (CD127 o
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016’, provides in depth analysis on Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted pipeline therapeutics. The report provides comprehensive information on the Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) targeted pipeline therapeutics. The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule typ
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016’, provides in depth analysis on Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics. The report provides comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), r
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016’, provides in depth analysis on Toll Like Receptor 4 (CD284 or TLR4) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development and features dormant and disco
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016’, provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted pipeline therapeutics. The report provides comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016’, provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics. The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit A
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
CaM Kinase (Ca2+-Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016’, provides in depth analysis on CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics. The report provides comprehensive information on the CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ca
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additiona
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500